Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
Marina Scolnik1, Gurkirpal Singh21Sección Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; 2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford,...
Enregistré dans:
Auteurs principaux: | Scolnik M, Singh G |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2011
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/cbb7ec01f6d74d8ca6ad9a9e76137d47 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
par: Roy Fleischmann
Publié: (2009) -
Serum anticyclic citrullinated protein antibody titers are correlated with the response to biological agents in patients with rheumatoid arthritis
par: Takahashi R, et autres
Publié: (2014) -
Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses
par: Datto C, et autres
Publié: (2013) -
Comparison of long-term efficacy between biological agents following tumor necrosis factor inhibitor failure in patients with rheumatoid arthritis: a prospective cohort study
par: Patricia Bogas, et autres
Publié: (2021) -
New developments in the treatment of osteoarthritis – focus on biologic agents
par: Torrero JI, et autres
Publié: (2015)